Cargando…

Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure

BACKGROUND/AIMS: To investigate the autoantibody against fumarate hydratase (FH), which is a specific liver failure-associated antigen (LFAA) and determine whether it can be used as a biomarker to evaluate the prognosis of acute-on-chronic liver failure (ACLF). METHODS: An immunoproteomic approach w...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Linlin, Wang, Ting, Chen, Sisi, Liu, Yeying, Huang, Xueying, Zheng, Sujun, Xu, Bin, Ren, Feng, Liu, Mei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial Office of Gut and Liver 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502492/
https://www.ncbi.nlm.nih.gov/pubmed/36317513
http://dx.doi.org/10.5009/gnl220022
_version_ 1785106333813440512
author Wei, Linlin
Wang, Ting
Chen, Sisi
Liu, Yeying
Huang, Xueying
Zheng, Sujun
Xu, Bin
Ren, Feng
Liu, Mei
author_facet Wei, Linlin
Wang, Ting
Chen, Sisi
Liu, Yeying
Huang, Xueying
Zheng, Sujun
Xu, Bin
Ren, Feng
Liu, Mei
author_sort Wei, Linlin
collection PubMed
description BACKGROUND/AIMS: To investigate the autoantibody against fumarate hydratase (FH), which is a specific liver failure-associated antigen (LFAA) and determine whether it can be used as a biomarker to evaluate the prognosis of acute-on-chronic liver failure (ACLF). METHODS: An immunoproteomic approach was applied to screen specific LFAAs related to differential prognosis of ACLF (n=60). Enzyme-linked immunosorbent assay (ELISA) technology was employed for the validation of the frequency and titer of autoantibodies against FH in ACLF patients with different prognoses (n=82). Moreover, we clarified the expression of autoantibodies against FH in patients with chronic hepatitis B (n=60) and hepatitis B virus-related liver cirrhosis (n=60). The dynamic changes in the titers of autoantibodies against FH were analyzed by sample collection at multiple time points during the clinical course of eight ACLF patients with different prognoses. RESULTS: Ultimately, 15 LFAAs were screened and identified by the immunoproteomic approach. Based on ELISA-based verification, anti-FH/Fumarate hydratase protein autoantibody was chosen to verify its expression in ACLF patients. ACLF patients had a much higher anti-FH autoantibody frequency (76.8%) than patients with liver cirrhosis (10%, p=0.000), patients with chronic hepatitis B (6.7%, p=0.022), and normal humans (0%, p=0.000). More importantly, the frequency and titer of anti-FH protein autoantibodies in the serum of ACLF patients with a good prognosis were much higher than that of patients with a poor prognosis (83.9% vs 61.5%, p=0.019; 1.41±0.85 vs 0.94±0.56, p=0.017, respectively). The titer of anti-FH autoantibodies showed dynamic changes in the clinical course of ACLF. CONCLUSIONS: The anti-FH autoantibody in serum may be a potential biomarker for predicting the prognosis of ACLF.
format Online
Article
Text
id pubmed-10502492
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial Office of Gut and Liver
record_format MEDLINE/PubMed
spelling pubmed-105024922023-09-16 Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure Wei, Linlin Wang, Ting Chen, Sisi Liu, Yeying Huang, Xueying Zheng, Sujun Xu, Bin Ren, Feng Liu, Mei Gut Liver Original Article BACKGROUND/AIMS: To investigate the autoantibody against fumarate hydratase (FH), which is a specific liver failure-associated antigen (LFAA) and determine whether it can be used as a biomarker to evaluate the prognosis of acute-on-chronic liver failure (ACLF). METHODS: An immunoproteomic approach was applied to screen specific LFAAs related to differential prognosis of ACLF (n=60). Enzyme-linked immunosorbent assay (ELISA) technology was employed for the validation of the frequency and titer of autoantibodies against FH in ACLF patients with different prognoses (n=82). Moreover, we clarified the expression of autoantibodies against FH in patients with chronic hepatitis B (n=60) and hepatitis B virus-related liver cirrhosis (n=60). The dynamic changes in the titers of autoantibodies against FH were analyzed by sample collection at multiple time points during the clinical course of eight ACLF patients with different prognoses. RESULTS: Ultimately, 15 LFAAs were screened and identified by the immunoproteomic approach. Based on ELISA-based verification, anti-FH/Fumarate hydratase protein autoantibody was chosen to verify its expression in ACLF patients. ACLF patients had a much higher anti-FH autoantibody frequency (76.8%) than patients with liver cirrhosis (10%, p=0.000), patients with chronic hepatitis B (6.7%, p=0.022), and normal humans (0%, p=0.000). More importantly, the frequency and titer of anti-FH protein autoantibodies in the serum of ACLF patients with a good prognosis were much higher than that of patients with a poor prognosis (83.9% vs 61.5%, p=0.019; 1.41±0.85 vs 0.94±0.56, p=0.017, respectively). The titer of anti-FH autoantibodies showed dynamic changes in the clinical course of ACLF. CONCLUSIONS: The anti-FH autoantibody in serum may be a potential biomarker for predicting the prognosis of ACLF. Editorial Office of Gut and Liver 2023-09-15 2022-11-01 /pmc/articles/PMC10502492/ /pubmed/36317513 http://dx.doi.org/10.5009/gnl220022 Text en Copyright © Gut and Liver. https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Wei, Linlin
Wang, Ting
Chen, Sisi
Liu, Yeying
Huang, Xueying
Zheng, Sujun
Xu, Bin
Ren, Feng
Liu, Mei
Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
title Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
title_full Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
title_fullStr Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
title_full_unstemmed Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
title_short Serum Anti-Fumarate Hydratase Autoantibody as a Biomarker for Predicting Prognosis of Acute-on-Chronic Liver Failure
title_sort serum anti-fumarate hydratase autoantibody as a biomarker for predicting prognosis of acute-on-chronic liver failure
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10502492/
https://www.ncbi.nlm.nih.gov/pubmed/36317513
http://dx.doi.org/10.5009/gnl220022
work_keys_str_mv AT weilinlin serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT wangting serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT chensisi serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT liuyeying serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT huangxueying serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT zhengsujun serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT xubin serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT renfeng serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure
AT liumei serumantifumaratehydrataseautoantibodyasabiomarkerforpredictingprognosisofacuteonchronicliverfailure